RevenanasBook a free audit

Signals 

/

Funding Signal

Funding Signal

Quadlytics Inc. Secures $3.8M in Latest Funding Round

November 7, 2026

SaaS & Software

Series B

$3.8M

Series B

Key Facts

Company

Quadlytics Inc.

Amount Raised

$3,798,690

Round

Series B

Employees

6

What Happened

Quadlytics Inc., a technology firm focused on healthcare, officially announced a significant funding round on November 7, 2026. The company successfully secured $3,798,690 in a Series B funding round. This Quadlytics I news indicates continued investor confidence in their innovative approach to healthcare technology.

This latest investment will likely fuel further development and expansion for Quadlytics I. Details regarding Quadlytics I competitors and Quadlytics I pricing strategies will be closely watched as the company leverages this capital.

Who Is Quadlytics I

Founded with a mission to revolutionize epilepsy care, Quadlytics Inc. is developing AI-powered technology to address seizure unpredictability. The company's platform combines wearable sensing and machine learning to provide timely insights for patients and caregivers.

Quadlytics Inc. operates as a B2B signal intelligence platform, though its core focus is on medical applications. It provides market event monitoring software capabilities within the healthcare sector, aiming to support clinicians with relevant data for care discussions.

What Does Quadlytics I Do

The Quadlytics Inc. platform is designed to detect anomalous physiological changes from wearable data. This enables earlier preparation and more informed decision-making for individuals managing epilepsy.

Their technology supports a new model of proactive epilepsy care, helping patients live with greater confidence and independence. For B2B sales teams targeting the healthcare sector, understanding this revenue signal detection can be crucial. The platform's ability to generate B2B buying intent from market events, specifically health-related data, makes it a unique player.

While currently under development and not yet available for clinical use, the system's focus on signal-based lead scoring for sales teams in the medical device and pharmaceutical industries could be transformative. It provides a specialized form of intent data for B2B sales, offering deep insights into patient needs and care trends.

SaaS & Software Market Context

The SaaS and software market continues to attract substantial investment, with many companies announcing their latest SaaS & software funding rounds. This trend is driven by the increasing demand for specialized, data-driven solutions across various industries.

SaaS & software funding news 2026 highlights a strong appetite among SaaS & software venture capital firms for innovative startups. Quadlytics Inc.'s funding aligns with broader trends seeing significant capital flowing into SaaS & software startups to watch 2026, particularly those leveraging AI and machine learning for niche applications.

While M&A activity is also notable in SaaS & software M&A 2026, funding rounds like this demonstrate continued growth and expansion in the sector, especially for companies addressing critical challenges with advanced technology.

Why This Matters

This funding round for Quadlytics Inc. signifies a growing interest in AI-driven healthcare solutions. It positions the company to accelerate its product development and potentially expand its market reach, putting it in closer competition with data intelligence providers like Crunchbase in the specialized healthcare data analytics market.

For B2B vendors, this signal creates immediate opportunities. Quadlytics Inc. will likely be investing in new technologies, talent, and partnerships, generating private company funding signals for various service providers. This could include demand for cloud infrastructure, cybersecurity solutions, and specialized consulting services as they scale operations.

The investment also underscores the value of technology IPO pipeline alerts for companies in adjacent sectors, as successful funding rounds often precede further growth and market expansion.

What to Watch

In the next 6-12 months, we should anticipate Quadlytics Inc. to focus heavily on clinical trials and regulatory approvals for its epilepsy care platform. This funding will enable significant hiring, particularly in engineering, data science, and clinical research roles. We may also see strategic partnerships with healthcare providers or medical device manufacturers as they prepare for market entry and potential Quadlytics I reviews.

Source:

Get signals like this sent to your CRM

We build signal infrastructure that detects market moves and routes them to your team — automatically.

Book a 15 min call
Dominykas Rukas - Revenanas

More from this industry

    We can send changes like these to your own CRM, matched to the accounts your team sells to.

    Book a free audit

    Built in your tools.
    Run by your team.

    Tell us the commercial goal and where it gets stuck. We find the bottleneck with you and plan the first two week sprint from it.

    Dominykas Rukas, RevenanasDominykas RukasCo-founderBook a free audit
    • HubSpot partner badgeHubSpot partner
    • Enterprise Clay partner